InsightRX Precision Medicine Technology to Help Improve Care of Patients Receiving Stem Cell Transplants | national news

SAN FRANCISCO, 22 November 2021 / PRNewswire / – InsightRX, which provides a cloud-based precision assay platform to help guide treatment decisions, today announced that Memorial Sloan Kettering Cancer Center (MSK) has implemented its Precision assay platform for tailoring the dosage of certain chemotherapy drugs and immunosuppressants used in the delivery of stem cell transplants to patients with hematologic malignancies and other cancers.

The InsightRX Nova platform helps select patient-specific doses of the chemotherapy drugs busulfan and fludarabine, as well as the anti-thymocyte globulin (ATG) immunosuppressant, for adult and pediatric patients receiving stem cell transplants.

Stem cell transplants are usually preceded by a chemotherapy conditioning regimen that destroys cancer cells and suppresses the patient’s immune response to donor cells. The dose needed to achieve the desired drug exposure is not standardized and differs based on individual factors such as weight, height, underlying health, metabolism, and previous drug levels.

Accurate dosing is essential to maximize the effectiveness of conditioning regimens, which have a “narrow therapeutic window” because their dose must be high enough to prevent disease relapse or graft failure, but low enough to prevent disease relapse or graft failure. avoid harmful side effects. In the case of busulfan and fludarabine, these can be life-threatening conditions such as sinusoidal obstruction syndrome (SOS), which damages the liver, and acute graft versus host disease (aGvHD). , which occurs when donor cells attack the host’s organs and tissues after a stem cell transplant. The five-year term cumulative death rate for leukemia patients receiving a stem cell transplant is approximately 50%, with relapse, infection and GvHD being the leading causes of death.

“We are proud to collaborate with Memorial Sloan Kettering as he continues to innovate in cancer treatment and research to improve patient care and outcomes,” said Sirj Goswami, PhD, CEO and co-founder from InsightRX. “This reflects the growing emphasis on expanding precision medicine beyond the selection of targeted drugs to ensure that every patient receiving complex drugs receives the right dose for them. “

The InsightRX Nova cloud-based precision assay platform uses patient-specific data, pharmacokinetic / pharmacodynamic (PK / PD) models, and Bayesian predictions to understand a patient’s unique pharmacological profile and guide patient decisions. processing.

A second generation Bayesian pharmacokinetic (PK) model co-developed by InsightRX and researchers at University of California, San Francisco (UCSF), has shown unprecedented accuracy and precision in meeting busulfan dosing targets in a 2020 to study conditioning of busulfan before hematopoietic stem cell transplants (HCT) for myeloid cancers such as chronic myeloid leukemia (CML) and acute myeloid leukemia (AML).

The InsightRX Apollo real-time analytics platform captures and reports clinical and operational metrics to drive pharmacy quality improvement efforts.

About InsightRX

??InsightRX is a healthcare technology company that has developed a cloud-based platform for precision medicine and clinical analysis designed to individualize treatment at the point of care. The platform leverages patient-specific data, pharmacological models and machine learning to understand each patient’s unique pharmacological profile and can be seamlessly integrated into a clinical workflow. Learn more about the recently announced InsightRX $ 10 million Series A financing.

Media contact

Megan Moriarty

Amendola Communications for InsightRX


[email protected]

View original content to download multimedia:


Source link